Xue-Yi Pan's research while affiliated with First Affiliated Hospital of China Medical University and other places

Publications (13)

Article
Objective: To establish an immune gene prognostic model of acute myeloid leukemia (AML) and explore its correlation with immune cells in bone marrow microenvironment. Methods: Gene expression profile and clinical data of TCGA-AML were downloaded from TCGA database. Immune genes were screened by LASSO analysis to construct prognosis prediction mo...
Article
Purpose: Prediction models for acute myeloid leukemia (AML) are useful, but have considerable inaccuracy and imprecision. No current model includes covariates related to immune cells in the AML microenvironment. Here, an immune risk score was explored to predict the survival of patients with AML. Experimental Design: We evaluated the predictive acc...
Article
Full-text available
We aimed to establish a discriminative gene-expression-based classifier to predict survival outcomes of T-cell lymphoblastic lymphoma (T-LBL) patients. After exploring global gene-expression profiles of progressive (n = 22) vs. progression-free (n = 28) T-LBL patients, 43 differentially expressed mRNAs were identified. Then an eleven-gene-based cla...
Article
Full-text available
Purpose: Adults with T-cell lymphoblastic lymphoma (T-LBL) generally benefit from treatment with acute lymphoblastic leukemia (ALL)-like regimens, but approximately 40% will relapse after such treatment. We evaluated the value of CpG methylation in predicting relapse for adults with T-LBL treated with ALL-like regimens. Experimental design: A to...
Article
Full-text available
We aimed to characterize the clinical significance of epigenetic loss of death-associated protein kinase (DAPK) gene function through promoter methylation in the development and prognosis of lymphoma. PubMed, Web of Science and ProQuest databases were searched for relevant studies. Twelve studies involving 709 patients with lymphoma were identified...
Article
Full-text available
As a regulator of coagulation, abnormal Protein Z (PZ) expression may lead to the formation of blood clots in humans. While previous studies have shown that PZ protein is altered in several types of cancer, however, additional observations are needed to understand the complex biology involved. Herein, we investigated local alterations in PZ express...
Article
NK/T cell lymphoma (NKTCL) is a rare type of non-Hodgkin's lymphoma, occurs more frequently in Asia and Latin America. In China, NKTCL accounts for 30.1% in T-NHL and is highly related with EBV (Epstein-Barr virus) infection. This disease is highly aggressive, not sensitive to chemotherapy, with poor prognosis. The mean survival time is about 12-38...
Article
To explore the expression and clinical significance of Semaphorin4D (Sema4D) mRNA in peripheral blood lymphocyte, Sema4D on platelet surface, soluble Sema4D (sSema4D) in plasma in patients with cerebral infarction. Taking 299 patients with cerebral infarction as the case group while 195 healthy adults as the control group. The mRNA expression of Se...
Article
The blood of the patients with malignant tumors is in hypercoagulable state; its correlation to tumor migration evokes more and more attentions. Protein Z (PZ), a newly found anti-coagulation factor, is a vitamin K-dependent plasma protein which is synthesized by the liver. Its structure is very similar to the vitamin K-dependent coagulation factor...
Article
To study the alteration of protein Z (PZ) in patients with cardio-cerebral thrombotic diseases, its clinical significance and relations with FX. PZ and FX:Ag were measured by ELISA, and plasma FX:C by first stage method. In 170 patients with acute ischemic stroke (AIS), 40 acute myocardial infarction (AMI) and 60 healthy adults as contrast, PZ, FX:...

Citations

... Yi Zhang et al. constructed a novel prognostic scoring model for newly diagnosed FLT3-ITD-positive AML (23), but the model has some limitations such as induction and consolidation treatment regimens cannot be fully harmonized due to the retrospective nature of the study. Yun Wang et al. built an immune risk score to predict survival of patients with AML receiving chemotherapy (24), however, they lacked data on some important predictive covariates, such as mutation topography and results of MRD testing in subjects achieving a complete remission. Piyanuch Kongtim et al. constructed anovel disease risk model for patients with AML receiving allogeneic hematopoietic cell transplantation (25), while this is a retrospective study conducted in a single institution, and the limited number of patients in some subgroups may not detect relevant differences between the groups. ...
... With ALL pediatric-like treatments, the expected relapse incidence in adults is about 35% [ However, the definition of high-risk LBL is not standardized and far less well defined than in ALL. Prognostic tools including 5 miRNA-based or CpG-based classifiers together with clinical and genetics factors may show higher predictive accuracy [75,76]. Eastern Cooperative Oncology Group (ECOG) and/or NOTCH1/FBXW7 status (wild type) plus miRNA high-risk signatures could help identify the patients with more favorable response to HCT (Allo-HCT yes vs. no: 5-year DFS 48% vs. 25%; P = 0.003) [75]. ...
... And adult T-LBL patients with high nomogram score could benefit from the BFM regimen, which may contribute to precision therapy decision-making. 89 Moreover, a 4-CpGbased classifier showed a good predictive effect in adult T-LBL, and a prognostic model incorporating this classifier, PS, NOTCH1/FBXW7 status, LDH, and CNS involvement helped identify high-risk subgroups of adult T-LBL mostly benefited from HSCT. The therapeutic protocol with BFM followed by HSCT could significantly improve survival of high-risk adult T-LBL. ...
... As noted, methylation of these genes could serve as a risk marker or a potential therapeutic target [128,129]. Several methylation studies investigated the DAPK1 gene showing higher methylation significantly associated with lower OS, disease-specific survival, and 5-year survival in the DLBCL patient cohort [130,131]. In addition, a prognostic and predictive potential of increased DAPK1 methylation in plasma samples was revealed in DLBCL. ...
... 25,26 Additionally, the mRNA and protein expression levels of PROZ were elevated in lung adenocarcinoma cells compared to normal healthy lung tissues and might serve as a prognostic biomarker for lung cancer. 27 However, PROZ was found to be decreased in HCC tissues compared with control tissues and was significantly associated with overall survival in HCC. 28 This was consistent with the results of this study. ...
... PROZ is mainly synthesised in the liver and kidney tissues and then secreted into the blood. Although the plasma level of PZ has been reported to be decreased in cancers, such as acute leukaemia and acute lymphoblastic leukaemia, 18,19 the PROZ expression level was found to be increased in most cancer types, especially in advanced cancer stages. 18 The function of PROZ in tumorigenesis is still unknown. ...